Browsing Tag
Liquid Biopsy
6 posts
Can Freenome’s $1.1bn SPAC deal unlock a new chapter for blood-based multi-cancer detection?
Freenome merges with PCSC in $1.1B deal to go public as FRNM. Find out how its AI-powered blood tests could change early cancer detection.
Angle plc collapses after shock pivot: Executive chairman appointed as it rebrands to CelLBxHealth
Angle plc’s shares plunge 36 percent after rebranding as CelLBxHealth and appointing Jan Groen as executive chairman. Discover how this reset affects funding and investor outlook.
Tempus AI and Stemline Therapeutics partner to advance AI-driven ESR1 mutation testing in metastatic breast cancer
Tempus AI, Inc. (NASDAQ: TEM) and Stemline Therapeutics, Inc., a wholly owned subsidiary of the Menarini Group, have…
ANGLE plc signs deal with AstraZeneca to develop Parsortix-based AR detection assay for prostate cancer studies
In a deal valued at £550,000, ANGLE plc (AIM:AGL, OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating…
ANGLE plc collaborates with AstraZeneca on cutting-edge cancer detection technology
ANGLE plc, a leading innovator in liquid biopsy and circulating tumour cell (CTC) solutions, has announced a significant…
ANGLE plc announces cancer diagnosis breakthrough with DNA molecular analysis
ANGLE plc, a global leader in liquid biopsy technology, has recently achieved a major breakthrough in cancer diagnostics,…